In September, we added 83 citations in DIDB, including 44 in vitro (with 24 articles published in September 2024) and 39 in vivo articles (with 27 articles published in September 2024).
6 NDA/BLAs approved in 2024, including axatilimab (NIKTIMVO), deuroxolitinib (LEQSELVI), lazertinib (LAZCLUZE), nemolizumab (NEMLUVIO), palopegteriparatide (YORVIPATH), and vorasidenib (VORANIGO), were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.